Bauer J, Dapper F, Demirakça S, Knothe C, Thul J, Hagel K J
Department of Pediatric Cardiology, University of Giessen, Germany.
J Heart Lung Transplant. 1997 Dec;16(12):1238-47.
Pulmonary hypertension is responsible for a substantial part of perioperative and postoperative mortality and morbidity after cardiac transplantation. Treatment of right ventricular failure after increased pulmonary vascular resistance is difficult especially in infants and children. Therefore we started a preventive therapy of pulmonary hypertension after cardiac transplantation to avoid right ventricular failure and compared the results with a group of patients with conventional therapy.
Group 1 (n = 13), with transplantation from 1988 to 1991, was treated with vasodilators when symptoms of right ventricular failure developed. Group 2 (n = 19) had preventive treatment with prostaglandin E1 (PGE1), the phosphodiesterase-III inhibitor enoximone, and alkalinazation starting during weaning from cardiopulmonary bypass.
Six patients in group 1 died; four of them as the result of right ventricular failure in the immediate postoperative course despite aggressive treatment. In group 2 there were three deaths as the results of rejection (2) and infection (1). None of these patients developed right ventricular failure (p = 0.02). Cold ischemic time, extracorporeal circulation time, and waiting time before transplantation were significantly longer in group 2. Side effects of this preventive therapy were not observed.
We conclude that prophylactic therapy of pulmonary hypertension with vasodilators in infants and children after heart transplantation is safe and effective in preventing right ventricular failure in the postoperative course.
肺动脉高压是心脏移植围手术期和术后死亡率及发病率的重要原因。肺血管阻力增加后右心室衰竭的治疗困难,尤其是在婴幼儿中。因此,我们开展了心脏移植后肺动脉高压的预防性治疗以避免右心室衰竭,并将结果与一组接受传统治疗的患者进行比较。
第1组(n = 13),1988年至1991年接受移植,在出现右心室衰竭症状时用血管扩张剂治疗。第2组(n = 19)在脱离体外循环开始时接受前列腺素E1(PGE1)、磷酸二酯酶III抑制剂依诺昔酮和碱化的预防性治疗。
第1组有6例患者死亡;其中4例尽管积极治疗仍在术后早期因右心室衰竭死亡。第2组有3例因排斥反应(2例)和感染(1例)死亡。这些患者均未发生右心室衰竭(p = 0.02)。第2组的冷缺血时间、体外循环时间和移植前等待时间明显更长。未观察到这种预防性治疗的副作用。
我们得出结论,心脏移植后婴幼儿肺动脉高压的预防性血管扩张剂治疗在预防术后右心室衰竭方面是安全有效的。